中国实用外科杂志2016，Vol.36Issue(11)：1205-1210,6.DOI:10.7504/CJPS.ISSN1005-2208.2016.11.18
乳腺癌新辅助治疗病理完全缓解影响因素及预后分析
Analysis of the predicted factors of pathological complete response (pCR) after neoadjuvant systemic therapy in primary breast cancer and the prognostic value of pCR
摘要
Abstract
Objective To explore the predicted factors and the prognostic value of pathological complete response (pCR). Methods The clinical data of patients with primary breast cancer received neoadjuvant systemic therapy (NST),subsequent surgery between January 2008 and December 2014 in Breast Disease Center,Peking University First Hospital were analyzed retrospectively. Data of the pathological characteristics and events in follow-up were analyzed to explore the predicted factors and the prognostic value of pCR. Results The pCR rate was 21.9%,and the patients achieved a pCR had better survival than the patients who didn’t (DFS:P=0.003;OS:P=0.009). Different subtypes differed in pCR rate (P<0.001),Luminal B-like(HER2 negative),HER2 positive (non-luminal) and triple-negative breast cancer (TNBC) were easier to achieve a pCR (30.6%, 37.5% and 32.4% respectively). The predicted factors of pCR in the multivariate model are the PR status before NST(OR=0.297,95%CI=0.167-0.530,P<0.001),the HER2 status before NST(OR=2.351,95%CI=1.340-4.125,P=0.003),the Ki67 status before NST(OR=6.870,95%CI=0.885-53.303,P=0.065). Conclusion The predicted factors of pCR are the PR,HER2 and Ki67 expression before NST. PCR could be a predictor of DFS and OS,but its values differ in subtypes,and the correlationships have statistical significance in HER2 positive (non-luminal) and TNBC.关键词
乳腺癌/新辅助治疗/病理完全缓解/预后Key words
primary breast cancer/neoadjuvant systemic therapy/pathological complete response/prognosis分类
医药卫生引用本文复制引用
高国璇,张岩,张虹,徐玲,李挺,刘荫华..乳腺癌新辅助治疗病理完全缓解影响因素及预后分析[J].中国实用外科杂志,2016,36(11):1205-1210,6.基金项目
首都特色应用研究项目 （）
